Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial

摘要

Key PointsQuestionWhat are the associations between changes in visual acuity and changes in optical coherence tomographic central subfield thickness across 3 anti-vascular endothelial growth factor medications used for diabetic macular edema? FindingsIn a post hoc analysis of 652 participants in a randomized clinical trial, changes in central subfield thickness were compared with changes in visual acuity. Analysis showed that changes in central subfield thickness accounted for only a small proportion of the total variation in changes in visual acuity. MeaningThese findings do not support using changes in optical coherence tomography central subfield thickness as a surrogate for changes in visual acuity in phase 3 trials evaluating anti-vascular endothelial growth factor for diabetic macular edema or to guide physicians or patients about changes in visual acuity with anti-vascular endothelial growth factor treatment.